Differential Effects of β-Blockers on Albuminuria in Patients With Type 2 Diabetes
Why the study?
Does carvedilol reduce microalbuminuria more than metoprolol tartrate in patients with hypertension and type 2 diabetes on ACEi/ARB therapy?
Population
1,235 participants with hypertension and type 2 diabetes on background angiotensin-converting enzyme…
Comparison
Carvedilol titrated to achieve target blood… vs Metoprolol tartrate titrated to achieve target…
Design
RCT, Randomized to either metoprolol tartrate or carvedilol, Blinded
Follow-up
5 months
Authors
Discussion
Loading...
Member takes
Implication
Supports carvedilol over metoprolol tartrate in hypertensive T2DM on ACEi/ARB; extends evidence of differential beta-blocker effects on albuminuria.
Structured PICO
Does carvedilol reduce microalbuminuria more than metoprolol tartrate in patients with hypertension and type 2 diabetes on ACEi/ARB therapy?
P
Population
1,235 participants with hypertension and type 2 diabetes on background angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
I
Intervention
Carvedilol titrated to achieve target blood pressure for 5 months.
C
Comparator
Metoprolol tartrate titrated to achieve target blood pressure for 5 months.
O
Outcome
Changes in microalbuminuria (measured using spot urine albumin:creatinine ratio) at 5 months.surrogate
Carvedilol, unlike metoprolol tartrate, significantly reduces microalbuminuria in patients with hypertension and type 2 diabetes already receiving renin-angiotensin system blockade.
Cite This Study
Bakris et al. (2005) studied this question.